AU3279395A - Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes - Google Patents

Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Info

Publication number
AU3279395A
AU3279395A AU32793/95A AU3279395A AU3279395A AU 3279395 A AU3279395 A AU 3279395A AU 32793/95 A AU32793/95 A AU 32793/95A AU 3279395 A AU3279395 A AU 3279395A AU 3279395 A AU3279395 A AU 3279395A
Authority
AU
Australia
Prior art keywords
thioxanthenes
phenothiazines
disease
treating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU32793/95A
Other versions
AU708682B2 (en
Inventor
Peter Davies
Inez J Vincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of AU3279395A publication Critical patent/AU3279395A/en
Application granted granted Critical
Publication of AU708682B2 publication Critical patent/AU708682B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
AU32793/95A 1994-08-08 1995-08-07 Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes Ceased AU708682B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28733994A 1994-08-08 1994-08-08
US08/287339 1994-08-08
US34675794A 1994-11-30 1994-11-30
US08/346757 1994-11-30
PCT/US1995/010110 WO1996004915A1 (en) 1994-08-08 1995-08-07 Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Publications (2)

Publication Number Publication Date
AU3279395A true AU3279395A (en) 1996-03-07
AU708682B2 AU708682B2 (en) 1999-08-12

Family

ID=26964404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32793/95A Ceased AU708682B2 (en) 1994-08-08 1995-08-07 Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes

Country Status (5)

Country Link
EP (1) EP0778773A1 (en)
KR (1) KR970704445A (en)
AU (1) AU708682B2 (en)
CA (1) CA2196529A1 (en)
WO (1) WO1996004915A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB9713484D0 (en) * 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
DE19842416A1 (en) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Secondary amines for the prevention and therapy of diseases caused or intensified by oxidation processes
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
PT1470818E (en) * 2003-04-25 2006-11-30 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
JP5186212B2 (en) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド Method for chemical synthesis and purification of diaminophenothiazinium compounds such as methylthioninium chloride (MTC)
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2645919C (en) * 2006-03-29 2016-05-31 Wista Laboratories Ltd. Thioninium compounds and their use
ATE478058T3 (en) 2006-03-29 2010-09-15 Wista Lab Ltd 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
PT3851447T (en) 2006-10-12 2023-12-11 Bellus Health Inc Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
ES2331282B1 (en) * 2008-06-25 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) (45%) HYDRAZIDS OF HETEROCICLICAL SYSTEMS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES.
DE102010062810B4 (en) * 2010-09-07 2014-03-13 Immungenetics Ag 2- (R2-thio) -10- [3- (4-R1-piperazin-1-yl) -propyl] -10H-phenothiazines for the treatment of neurodegenerative diseases selected from beta-amyloidopathies and alpha-synucleinopathies
CN105853439A (en) 2011-02-11 2016-08-17 维斯塔实验室有限公司 Phenothiazine diaminium salts and their use
WO2012166862A1 (en) 2011-06-01 2012-12-06 Wisconsin Alumni Research Foundation Compositions and methods for treating alzheimer's disease
EP4241774A1 (en) * 2020-11-04 2023-09-13 Gliacelltech Inc. Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine
US20240025868A1 (en) * 2020-11-13 2024-01-25 Icahn School Of Medicine At Mount Sinai Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases
WO2023131606A1 (en) * 2022-01-04 2023-07-13 Immungenetics Ag Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837518A (en) * 1958-06-03 Phenthiazine compounds
US2902484A (en) * 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives and processes for their preparation
NL108827C (en) * 1956-04-09

Also Published As

Publication number Publication date
KR970704445A (en) 1997-09-06
AU708682B2 (en) 1999-08-12
WO1996004915A1 (en) 1996-02-22
CA2196529A1 (en) 1996-02-22
EP0778773A1 (en) 1997-06-18

Similar Documents

Publication Publication Date Title
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
AU1407399A (en) Treatment for alzheimer's disease
AU4621893A (en) Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
AU2830097A (en) Therapeutic method for treatment of alzheimer's disease
EP0951293A4 (en) Method for treating alzheimer's disease
EP0735870A4 (en) Use of pla 2? inhibitors as treatment for alzheimer's disease
AU2187992A (en) Composition and method for disease treatment
AU5508798A (en) Diagnostic and therapeutic reagents for alzheimer's disease
AU7397094A (en) Prevention and treatment of alzheimer's disease
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
IL114466A0 (en) A method for treating and preventing alzheimer's disease
AU7556994A (en) Methods for the diagnosis of alzheimer's disease
AU6932000A (en) Tacrine derivatives for treating alzheimer's disease
ZA989365B (en) Preparation for treating alzheimer's disease
AU4636993A (en) Diagnosing alzheimer's disease and schizophrenia
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
AU1496597A (en) 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's Disease
AU4137596A (en) Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method
EP0796621A3 (en) Preventing and treating periodontal disease
EP0866799A4 (en) Apolipoprotein e2 and treatment of alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
AU2752295A (en) Collapsible camp-bed or dog's bed

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired